22 14 14 90 mail@montebello.no
Hjem » Gastroenterologi » Legemiddelmonitorering » RidaScreen

RidaScreen

IFX - Infliximab Monitoring

RIDASCREEN® IFX Monitoring er en kvantitativ ELISA for måling av infliximab (IFX, Remicade®, anti-TNFα) og biosimilar Remsima®, Inflectra® og Flixabi® i humant serum 0g plasma.

Key features of RIDASCREEN® IFX Monitoring:

* KU Leuven (Belgium) was conducting the Taxit study which demonstrated the positive effect of therapeutic drug monitoring (TDM) of Infliximab (IFX) in regards to cost saving and therapy optimization. They are world leaders in drug monitoring.

ADM - Adalimumab Monitoring

RIDASCREEN® ADM Monitoring er en ELISA for kvantitativ bestemmelse av adalimumab (ADM, Humira®) i humat serum og plasma.

VDZ - Vedolizumab Monitoring

RIDASCREEN® VDZ Monitoring er en ELISA for kvantitativ bestemmelse av vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) i humat serum og plasma.

GLM - Golimumab Monitoring

RIDASCREEN® VDZ Monitoring er en ELISA for kvantitativ bestemmelse av golimumab (GLM, Simponi®) i humat serum og plasma.

RIDASCREEN® anti-Infliximab antistoffer

  • CE-marked versions of the ELISA tests of KU Leuven
  • Highly specific antibodies
  • Validated in clinical trials
  • Validated on automated ELISA readers (e.g. DSX®)

RIDASCREEN® anti-Adalimumab antistoffer

  • CE-marked versions of the ELISA tests of KU Leuven
  • Highly specific antibodies
  • Validated in clinical trials
  • Validated on automated ELISA readers (e.g. DSX®)